What are the potential causes of persistent multifocal patchy bone‑marrow edema in the ankle and hindfoot of an otherwise healthy 11‑year‑2‑month‑old (now 13‑year‑11‑month) male with chronic lower‑leg pain, normal inflammatory markers and fecal calprotectin, and a marked response to celecoxib (celebrex)?

Chronic Non-Bacterial Osteitis (CNO) is the Most Likely Diagnosis

Given the multifocal bone marrow edema persisting over 2 years, normal inflammatory markers, normal fecal calprotectin, and dramatic response to celecoxib (a COX-2 inhibitor), this presentation is most consistent with chronic non-bacterial osteitis (CNO), also known as chronic recurrent multifocal osteomyelitis (CRMO). 1

Key Diagnostic Features Supporting CNO

Clinical Presentation

• Multifocal bone involvement with ill-defined bone marrow edema affecting distal tibia, fibula, talus, calcaneum, cuboid, cuneiforms, and metatarsal bases—a distribution highly characteristic of CNO 1
• Chronicity with persistence over 2 years without progression to osteomyelitis or structural destruction 1
• Age at onset (11 years) falls within the typical pediatric CNO range, though CNO can present at any age 1

Laboratory Findings

• Normal inflammatory markers (ESR, CRP) do not exclude CNO, as many patients have normal or only mildly elevated acute phase reactants 1
• Normal fecal calprotectin effectively rules out inflammatory bowel disease (IBD), which can be associated with enthesitis and bone marrow edema in the context of spondyloarthropathy 2, 3

Imaging Characteristics

• Bone marrow edema without structural changes on initial MRI is typical of early CNO 1, 4
• Minimal post-contrast enhancement with persistent T2 hyperintensity over 2 years suggests a non-infectious, inflammatory process 1
• Small joint effusions without significant synovial thickening argues against septic arthritis or aggressive inflammatory arthritis 1

Therapeutic Response

• Dramatic response to celecoxib is highly characteristic of CNO, as NSAIDs (particularly COX-2 inhibitors) are first-line therapy and often produce marked symptom improvement 1, 5

Differential Diagnosis Considerations

Infectious Osteomyelitis (Ruled Out)

• Multifocal osteomyelitis can occur in pediatric patients, particularly in those under 6 years old 1
• However, the absence of fever, systemic symptoms, elevated inflammatory markers, and progression over 2 years makes bacterial osteomyelitis extremely unlikely 1
• Normal fecal calprotectin and lack of bacteremia further argue against infection 2

Inflammatory Arthritis/Spondyloarthropathy (Less Likely)

• Psoriatic arthritis or axial spondyloarthritis can present with bone marrow edema and enthesitis 1
• However, the absence of synovial thickening, lack of juxta-articular erosions, and normal inflammatory markers make these diagnoses less likely 1
• The multifocal bone involvement without predominant joint disease is more consistent with CNO than spondyloarthropathy 1

Transient Bone Marrow Edema Syndrome (Unlikely)

• This typically affects single joints (most commonly hip or knee) and resolves within 6-12 months 4
• The multifocal distribution and 2-year persistence exclude this diagnosis 4

Stress Reaction/Altered Biomechanics (Unlikely)

• While bone marrow edema from stress can occur in active children, it typically involves weight-bearing surfaces and resolves with rest 4
• The multifocal, symmetric distribution and persistence despite treatment argue against purely mechanical causes 4

Complex Regional Pain Syndrome (CRPS) (Unlikely)

• CRPS can cause bone marrow edema, but typically presents with severe pain, allodynia, autonomic changes, and soft tissue edema 4
• The absence of soft tissue edema on MRI and response to NSAIDs make CRPS unlikely 4

Recommended Diagnostic Workup

Additional Laboratory Testing

• HLA-B27 testing to evaluate for spondyloarthropathy overlap 1
• Anti-CCP and rheumatoid factor to exclude rheumatoid arthritis 1
• Bone turnover markers (alkaline phosphatase, calcium, parathyroid hormone, 25-hydroxy-vitamin D) to assess bone metabolism 1

Imaging Considerations

• Whole-body MRI or bone scintigraphy to identify clinically silent lesions, as CNO is often multifocal beyond the symptomatic site 1
• Follow-up MRI to monitor for development of structural changes (sclerosis, hyperostosis, soft tissue ossification) that would confirm CNO 1

Bone Biopsy (If Diagnosis Remains Uncertain)

• Percutaneous or surgical bone biopsy should be considered if the diagnosis remains inconclusive after clinical, laboratory, and imaging evaluation 1
• Biopsy would show sterile inflammation with lymphocytes, plasma cells, and fibrosis without organisms on culture 1

Treatment Approach

First-Line Therapy

• Continue celecoxib at current dose given the marked response 1
• NSAIDs are first-line therapy for CNO, with COX-2 inhibitors preferred due to better gastrointestinal safety profile 1, 6

Second-Line Options (If NSAIDs Insufficient)

• Methotrexate or sulfasalazine as disease-modifying agents 1
• Bisphosphonates (pamidronate or zoledronic acid) for refractory cases 1
• TNF inhibitors or IL-1 inhibitors for severe, refractory disease 1

Monitoring Strategy

• Serial MRI every 6-12 months to assess disease activity and structural progression 1
• Clinical assessment of pain, function, and quality of life 1
• Growth and development monitoring given the patient's age 1

Critical Pitfalls to Avoid

• Do not assume all bone marrow edema requires bone biopsy—the clinical context, normal labs, and therapeutic response strongly suggest CNO without need for invasive procedures 1, 4
• Do not discontinue celecoxib prematurely—CNO often requires prolonged NSAID therapy, and premature discontinuation leads to relapse 1
• Do not miss multifocal involvement—whole-body imaging is essential to identify clinically silent lesions that may require monitoring 1
• Do not delay referral to pediatric rheumatology—CNO requires specialized management and monitoring for complications including growth disturbances and structural bone damage 1